Separate Moderna, Novavax efforts focusing on combined COVID-19/flu vaccine
Two separate efforts are underway to provide the public with a combination vaccine that would deliver simultaneous protections against COVID-19 and influenza. Moderna today announced its effort during a research-and-development presentation, in which a vaccine would be encoded for the COVID-19 spike protein and flu hemagglutinin glycoproteins. Novavax yesterday said its own effort, which is in a phase 1/2 clinical trial, combines within a single formulation its recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates with a patented saponin-based adjuvant.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…